Nalu Medical, Inc.
$5.7M 9,707 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ascendis Pharma Inc
Ascendis Pharma Inc reported $5,707,429.13 across General Payments, Research, and Ownership to 2,549 physicians and teaching hospitals across 4,744 transactions.
- $5.7M Top quartile payer
- All-tracks total
- 4,744 Top quartile volume
- Transactions
- 2,549 Top quartile reach
- Recipients
- −$933.6K
- General Payments vs PY2023
Ascendis Pharma Inc reported $5,707,429.13 across all CMS Open Payments tracks (General + Research + Ownership) to 2,549 physicians and teaching hospitals in Program Year 2024 - ranking #256 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $470,377.73, averaging $2.2K per recipient.
How Ascendis Pharma Inc's $5.7M all-tracks total breaks down
Ascendis Pharma Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
47/100
Total payments
D
63/100
Transaction volume
F
44/100
Physician reach
F
29/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ascendis-pharma-inc Ascendis Pharma Inc
$5.7M · #256/1,925 · 0.0% industry · PY2024
- TOT $5.7M
- RANK #256
- SHARE 0.0%
- TXN 4,744
- RCP 2,549
- CAT 4
- GEN $470.4K
- ΔGEN −$933.6K
- TOP1 15.4%
- PY 2024
Volume peers
Nearest volume peer: Nalu Medical, Inc. ($5.7M)
Ascendis Pharma Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ascendis Pharma Inc's CMS-reported General Payments decreased by $933.6K (−66.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ASCENDIS PHARMA ENDOCRINOLOGY INCPY2023: ASCENDIS PHARMA ENDOCRINOLOGY INCPY2024: Ascendis Pharma Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,403,988.93
- PY2024
- $470,377.73
What the Data Shows for Ascendis Pharma Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Ascendis Pharma Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
110 transactions worth $306.0K make "Compensation for Services Other Than Consulting" the top general-payment category in the 4-category breakdown below, 65.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Ascendis Pharma Inc's largest category was "Compensation for Services Other Than Consulting" at $306.0K - 65.0% of General Payments.
Ascendis Pharma Inc reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (65.0%), Food and Beverage (14.5%), and Consulting Fee (10.4%). The remaining 1 category make up 10.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ascendis Pharma Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $306.0K | 110 | 65.0% |
| Food and Beverage | $68.2K | 2,239 | 14.5% |
| Consulting Fee | $48.8K | 21 | 10.4% |
| Travel and Lodging | $47.3K | 179 | 10.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $259,090.48 (55.1%) of $470,377.73 in this company's General Payments records across 1,259 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ascendis Pharma Inc
The five named recipients with the highest reported General Payments from this company
- 1
Aristides Maniatis
$72,556.88 across 83 reported transactions
- 2
Toni Kim
$58,843.67 across 77 reported transactions
- 3
Joshua Yang
$49,244.26 across 70 reported transactions
- 4
Nidhi Gupta
$39,728.90 across 48 reported transactions
- 5
Philippe Backeljauw
$38,716.77 across 41 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ascendis Pharma Inc ranks #256 of 1,925 by total payments (top 13% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,176 of 1,838 by HHI (bottom 36% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Neurent Medical Limited : $525.6K total payments, HHI 699
- Medexus Pharma, Inc. : $75.6K total payments, HHI 698
- BK Medical Holding Company Inc. : $164.8K total payments, HHI 693
- HEMA Biologics, LLC : $276.5K total payments, HHI 691
- Precision Spine, Inc. : $802.9K total payments, HHI 690
- Kuraray America Inc. : $352.3K total payments, HHI 690
- Ascendis Pharma Inc (this company) : $470.4K total payments, HHI 686
- Distalmotion US : $620.2K total payments, HHI 685
- Maxx Orthopedics, Inc. : $96.6K total payments, HHI 683
- Janssen Scientific Affairs, LLC : $5.7M total payments, HHI 681
- Dentsply Sirona Inc : $10.4M total payments, HHI 679
- Swedish Orphan Biovitrum Ab : $276.4K total payments, HHI 679
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ascendis Pharma Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ascendis Pharma Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ascendis Pharma Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Providence Medical Technology, Inc.
$5.6M 2,215 recipients
Compare payment profiles
Highridge Medical LLC
$5.8M 2,278 recipients
Compare payment profiles
Marinus Pharmaceuticals, Inc.
$5.6M 988 recipients
Compare payment profiles
Linvatec Corporation
$5.8M 2,929 recipients
Compare payment profiles
Karyopharm Therapeutics Inc.
$5.6M 5,247 recipients
Compare payment profiles
Put this to use
Ascendis Pharma Inc ranks #256 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Ascendis Pharma Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Ascendis Pharma Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.